TY - JOUR
T1 - Process analysis of procalcitonin monitoring within community hospitals
AU - Peña, Kelsey
AU - Cooper, Mandelin
AU - Greer, Nickie
AU - Elders, Ty
AU - Septimus, Edward
N1 - Publisher Copyright:
© American Society of Health-System Pharmacists 2020. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose. Monitoring of procalcitonin (PCT) levels may support appropriate antibiotic discontinuation. The purpose of this study was to determine the current state of PCT monitoring at community hospitals across the United States. Methods. Data from adult patients who were admitted to community hospitals affiliated with a large healthcare system between August 1, 2016, and July 31, 2017, and who received antibiotics were evaluated for the number of PCT levels drawn and the timing between multiple levels. Data from eligible patients were evaluated for the discontinuation of antibiotics after meeting prespecified PCT thresholds for discontinuation of therapy, namely, a PCT measurement of <0.5 μg/L or a decrease of ≥80% from a previous peak value. Results. PCT levels were evaluated for 103, 913 patient data sets collected from 136 hospitals. Of these, 70% of the data sets showed a single PCT level drawn, and approximately 30% (30, 887) of the data sets showed multiple levels drawn. The first PCT measurement was drawn within 36 hours of antibiotic initiation in 96% of the patients. Of those with multiple levels, 23% (7,089) had levels drawn 24 to 72 hours apart. A small proportion (20% [6, 127]) of the patients with multiple levels were eligible for evaluation of appropriate antibiotic discontinuation. Of these, 1, 973 (32.2%) patients had antibiotics discontinued within 36 hours of meeting the prespecified PCT thresholds; these patients had a mean duration of antibiotic therapy of 6.1 days with a median of 4.7. Conclusion. Additional standardization of ongoing PCT monitoring and education regarding the appropriate discontinuation of antibiotics when thresholds are reached could aid in the use of this biomarker in support of antibiotic and laboratory stewardship.
AB - Purpose. Monitoring of procalcitonin (PCT) levels may support appropriate antibiotic discontinuation. The purpose of this study was to determine the current state of PCT monitoring at community hospitals across the United States. Methods. Data from adult patients who were admitted to community hospitals affiliated with a large healthcare system between August 1, 2016, and July 31, 2017, and who received antibiotics were evaluated for the number of PCT levels drawn and the timing between multiple levels. Data from eligible patients were evaluated for the discontinuation of antibiotics after meeting prespecified PCT thresholds for discontinuation of therapy, namely, a PCT measurement of <0.5 μg/L or a decrease of ≥80% from a previous peak value. Results. PCT levels were evaluated for 103, 913 patient data sets collected from 136 hospitals. Of these, 70% of the data sets showed a single PCT level drawn, and approximately 30% (30, 887) of the data sets showed multiple levels drawn. The first PCT measurement was drawn within 36 hours of antibiotic initiation in 96% of the patients. Of those with multiple levels, 23% (7,089) had levels drawn 24 to 72 hours apart. A small proportion (20% [6, 127]) of the patients with multiple levels were eligible for evaluation of appropriate antibiotic discontinuation. Of these, 1, 973 (32.2%) patients had antibiotics discontinued within 36 hours of meeting the prespecified PCT thresholds; these patients had a mean duration of antibiotic therapy of 6.1 days with a median of 4.7. Conclusion. Additional standardization of ongoing PCT monitoring and education regarding the appropriate discontinuation of antibiotics when thresholds are reached could aid in the use of this biomarker in support of antibiotic and laboratory stewardship.
KW - Antibiotic stewardship
KW - Biomarkers
KW - Calcitonin
KW - Community hospitals
KW - Procalcitonin
UR - http://www.scopus.com/inward/record.url?scp=85082791456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082791456&partnerID=8YFLogxK
U2 - 10.1093/ajhp/zxaa028
DO - 10.1093/ajhp/zxaa028
M3 - Article
C2 - 32236452
AN - SCOPUS:85082791456
SN - 1079-2082
VL - 77
SP - 632
EP - 635
JO - American Journal of Health-System Pharmacy
JF - American Journal of Health-System Pharmacy
IS - 8
ER -